YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Discover Continuous
Calm In Uveitis

YUTIQ is designed to deliver a sustained
release of fluocinolone for patients with chronic
noninfectious posterior uveitis for up to 36 months1

Now with a siliconized needle

This site is intended for US healthcare professionals only.


480 Pleasant Street
Suite B300
Watertown, MA 02472
1-833-EyePoint (1-833-393-7646)

480 Pleasant Street
Suite B300
Watertown, MA 02472
1-833-EyePoint (1-833-393-7646)

This site is intended for US healthcare professionals only.


YUTIQ: proven to reduce uveitis recurrence1

At 6 months—18% for YUTIQ and 79% for sham [95% Cl*: 60% (41%, 73%)] for study 1 and 22% for YUTIQ and 54% for sham [95% CI: 32% (15%, 48%)] for study 2 (P<0.1). At 12 months—28% for YUTIQ and 86% for sham [95% CI: 58% (40%, 70%)] for study 1 and 33% for YUTIQ and 60% for sham [95% CI: 27% (9%, 43%)] for study 2.

Extended median time to first recurrence of uveitis1,2

At 12 months—NE for YUTIQ/92 days for sham in study 1; NE for YUTIQ/187 days for sham in study 2.

Study design: The efficacy of YUTIQ was assessed in 2 randomized, multicenter, sham-controlled, double-masked, phase 3 studies in adult patients [N=282] with noninfectious uveitis affecting the posterior segment of the eye. The primary endpoint in both studies was the proportion of patients who experienced recurrence of uveitis in the study eye within 6 months of follow-up; recurrence was also assessed at 12 months. Recurrence was defined as either deterioration in visual acuity, vitreous haze attributable to noninfectious uveitis, or the use of confounding medications.1

*Confidence interval.

NE=non-evaluable due to the low number of recurrences in the YUTIQ group.2

YUTIQ: innovation in chronic noninfectious uveitis treatment

The YUTIQ implant is 3.5 mm long.

An image of a dime with the YUTIQ implant laying on top for scale

Uveitis specialists and retina specialists trust YUTIQ

Video thumbnail of Dr. Sumit Sharma discussing uveitis treatment and patient types.
Play Video

Dr Sumit Sharma

Dr Sharma, a uveitis specialist at the Cleveland Clinic, discusses treatment challenges, the various patient types, and best treatment practices.

Video thumbnail of Dr. David Eichenbaum discussing ideal patient, use and follow-up care for YUTIQ.
Play Video

Dr David Eichenbaum

Retina specialist Dr Eichenbaum discusses the ideal YUTIQ patient, use of YUTIQ, and follow-up care.

To hear more specialists discuss chronic noninfectious posterior uveitis and treatment with YUTIQ, please visit our

Comprehensive reimbursement and access services for your office and your patients

Submit a patient through the EyePoint Assist HCP Portal

The EyePoint Assist HCP Portal allows you to submit patients for a benefits investigation, confirm insurance eligibility, and gain access to financial and reimbursement support. To learn more, call 1-833-EyePoint for assistance. (1-833-393-7646)
EyePoint Assist Logo

New users: register for the portal

Download this onboarding form to sign up today.

Registered users: sign in to the portal

This link takes you directly to the EyePoint Assist HCP Portal.

Enroll a patient in EyePoint Assist

Download this form. Once completed, fax to 1-866-783-3124.

Visit the EyePoint Assist access and reimbursement page

YUTIQ® box